Piscataway, NJ, February 29, 2024–Camber Pharmaceuticals is pleased to announce the addition of Oxcarbazepine Oral Suspension, USP to its current portfolio.
Oxcarbazepine Oral Suspension, USP is indicated for:
- Adults as monotherapy or adjunctive therapy in the treatment of partial-onset seizures.
- Pediatrics as monotherapy in the treatment of partial-onset seizures in children 4 to 16 years of age, and as adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years of age.
Oxcarbazepine Oral Suspension, USP 300 mg/5 mL is available in 250 mL bottles.
To find out more about Oxcarbazepine Oral Suspension, USP, please visit www.camberpharma.com/oxcarbazepineoralsuspension
